The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial

Recruiting now

Conditions studied: Multiple Myeloma

In brief

This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.

Key facts

Study ID

NCT06228794

Run by

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

People needed

458

Starts

2024-04-01

Expected to finish

2027-12-01

Last updated by the study team

2025-05-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following inclusion criteria.
• Newly diagnosed multiple myeloma patients.
• Patients without any previous anti-myeloma treatment.
• Age: 18-80years old (adult).
• No history of cancer.
• Informed consent.

You may not qualify if…

• Patients meeting any of the following exclusion criteria will not be included in the study.
• Received therapy for multiple myeloma.
• Patients diagnosed with monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, waldenstrom macroglobulinemia or POEMS.
• Imminent or emerging infection.
• Known to be seropositive for a history of HIV.
• A participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial.
• Known or suspected of not being able to comply with the study protocol.

Where it is running

• Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.